Shanghai, China, November 20, 2023‌ – Usynova Pharmaceuticals Ltd. ("Usynova") today announced a global exclusive licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for its preclinical-stage small-molecule candidate drug UA022 targeting KRASG12D mutations.

Usynova Pharmaceuticals Ltd. recently announced that its independent-developed new biological agent UA007 successfully completed the phase I clinical trial of gout.

Recently, Usynova Pharmaceuticals Ltd. announced the completion of Series A financing of over RMB 200 million. This round of financing is led by Shenzhen Share Capital, followed by Zhangjiang Haoheng and Yingke capital. The original shareholders continue to participate in this round of investment.

On 16 September, Tee Labs, a biopharmaceutical innovation incubator managed by Shanghai TF Pharmaceutical Technology Co., Ltd., held an opening ceremony. Located in Shanghai Zhangjiang Hi-Tech Park, the incubator focuses on building an international biopharmaceutical innovation service platform, providing start-ups with a full range of support including R&D premises, supply services, operation management, investment and financing, and working with entrepreneurs to create breakthrough technologies and products that improve human health.

Shanghai, China, August 5, 2021 - Insilico Medicine, an industry leader in artificial intelligence for drug discovery, and Usynova announced to reach strategic cooperation.

On April 8, 2021, Usynova Pharmaceuticals Ltd. and Wuxi Apptec Co., Ltd., a subsidiary of WuXi AppTec, signed a cooperation agreement on Class 1 innovative drugs in Shanghai. The signing ceremony was attended by Li Jinsong, Chairman of Usynova,Hu Tao, Chief Executive Officer, Peng Shengbin, Chief Scientific Officer, and Wang Xi, Vice President of Operations, Chen Shuhui, Research President of WuXi AppTec, Chen Zhizhong, Vice President of Domestic New Drug R&D Service Department, and related personnel.